The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Open accessAbstract
BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No sufficient safety and efficacy data are available for DAPT with reduced-dose ticagrelor beyond 3 years”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
In the citing paper
“Reduced-dose ticagrelor (60 mg) decreased MACE compared with placebo (7.77% vs. 9.04%, respectively; HR 0.84; 95% CI, 0.74-0.95;P = 0.004; NNT 79), with no heterogeneity with respect to the diabetes sub-group”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
In the citing paper
“whereas it significantly increased TIMI major bleeding (2.3% vs. 1.06%, respectively; HR 2.32; 95% CI, 1.68-3.21;NNH 81)”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
In the citing paper
“dyspnoea, serious adverse events, and drug discontinuation rates.317”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E., Green, L. A., Hand, M. M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,348
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationAuthors Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,890
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,802
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Self-citation
Cited by
Sorted by citations
Items 101–200 of 999
Bonaca, M. P., Bhatt, D. L., Steg, P. G., Storey, R. F., Cohen, M. C., Im, K., Ophuis, T. O., Budaj, A., Goto, S., Lopez-Sendon, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv531 · Cited by 166
Self-citationChallenges in secondary prevention after acute myocardial infarction: A call for action
Piepoli, M. F., Corrà, U., Dendale, P., Frederix, I., Prescott, E., Schmid, J. P., Cupples, M., Deaton, C., Doherty, P., Giannuzzi, P., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316663873 · Cited by 177
Hess, C. N., Norgren, L., Ansel, G. M., Capell, W. H., Fletcher, J., Fowkes, F. G. R., Gottsäter, A., Hitos, K., Jaff, M. R., Nordanstig, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.024469 · Cited by 168
Risk Factor Burden and Long‐Term Prognosis of Patients With Premature Coronary Artery Disease
Zeitouni, M., Clare, R. M., Chiswell, K., Abdulrahim, J. W., Shah, N. P., Pagidipati, N. J., Shah, S. H., Roe, M. T., Patel, M. R., & Jones, W. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017712 · Cited by 166
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 170
Self-citationF. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046448 · Cited by 158
Self-citationThe Platelet Response to Tissue Injury
Eisinger, F., Patzelt, J., & Langer, H. F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00317 · Cited by 164
Role of aspirin in primary prevention of cardiovascular disease
Patrono, C., & Baigent, C. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0225-y · Cited by 163
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
Teng, R. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0290-2 · Cited by 160
“major bleeding versus placebo [16].”
Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules
Khodadi, E. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09555-4 · Cited by 154
The myth of ‘stable’ coronary artery disease
Fox, K. A. A., Metra, M., Morais, J., & Atar, D. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0233-y · Cited by 155
Ischemic Heart Disease: An Update
Jensen, R. V., Hjortbak, M. V., & Bøtker, H. E. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.007 · Cited by 163
Rocca, B., Fox, K. A. A., Ajjan, R., Andreotti, F., Baigent, C., Collet, J., Grove, E. L., Halvorsen, S., Huber, K., Morais, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy066 · Cited by 154
Self-citationTicagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting
Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1038 · Cited by 149
Self-citationPlatelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target
Ziegler, M., Wang, X., & Peter, K. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz070 · Cited by 148
“However, ticagrelor treatment was associated with an increased risk of severe bleeding complications.(97) Beneficial effects of prasugrel were reported in the TRITON-TIMI 38 trial(104) and beneficial effects of cangrelor in the CHAMPION PCI trial.”
BackgroundLindholm, D. P., Lindbäck, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., Hagström, E., Held, C., Köenig, W., Östlund, O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.030 · Cited by 143
Self-citationMyocardial Infarction in the ISCHEMIA Trial
CHAITMAN, B. R., Alexander, K. P., Cyr, D. D., Berger, J. S., Reynolds, H. R., Bangalore, S., Boden, W. E., Lópes, R. D., Demkow, M., Perna, G. P., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047987 · Cited by 139
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 197
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 139
Self-citationJones, W. S., Baumgärtner, I., Hiatt, W. R., Heizer, G., Conte, M. S., White, C. J., Berger, J. S., Held, P., Katona, B. G., Mahaffey, K. W., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025880 · Cited by 134
Self-citation2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 147
Oral Antiplatelet Therapy After Acute Coronary Syndrome
Kamran, H., Jneid, H. M., Kayani, W. T., Virani, S. S., Levine, G. N., Nambi, V., & Khalid, U. (2021) · JAMA · doi:10.1001/jama.2021.0716 · Cited by 134
Schiele, F., Gale, C. P., Bonnefoy‐Cudraz, E., Capuano, F., Claeys, M. J., Danchin, N., Fox, K. A. A., Huber, K., Iakobishvili, Z., Lettino, M., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616643053 · Cited by 134
Current concepts and novel targets for antiplatelet therapy
Gawaz, M., Geisler, T., & Borst, O. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00854-6 · Cited by 139
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
Storey, R. F., Angiolillo, D. J., Bonaca, M. P., Thomas, M. R., Judge, H. M., Rollini, F., Franchi, F., Ahsan, A., Bhatt, D. L., Kuder, J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.062 · Cited by 127
Self-citationManagement of Antithrombotic Therapy after Acute Coronary Syndromes
Rodríguez, F., & Harrington, R. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1607714 · Cited by 133
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 162
Self-citationProtective Effects of Ticagrelor on Myocardial Injury After Infarction
Vilahur, G., Gutiérrez, M., Casaní, L., Varela, L. M., Capdevila, A., Pons‐Lladó, G., Carreras, F., Carlsson, L. G., Hidalgo, A., & Badimón, L. (2016) · Circulation · doi:10.1161/circulationaha.116.024014 · Cited by 124
Capodanno, D., Bhatt, D. L., Eikelboom, J. W., Fox, K. A. A., Geisler, T., Gibson, C. M., González‐Juanatey, J. R., James, S. K., Lópes, R. D., Mehran, R., et al. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0314-y · Cited by 123
“In patients with prior MI, ticagrelor 60 mg bid is approved for long-term DAPT, based on the results of the PEGASUS (Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome) trial.(4) Because prior MI represented an inclusion criterion for COMPASS, a proportion”
MethodSelf-citationThe Role of Clopidogrel in 2020: A Reappraisal
Patti, G., Micieli, G., Cimminiello, C., & Bolognese, L. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/8703627 · Cited by 129
“Although there was no significant difference in the rate of serious adverse events between groups, permanent discontinuation was more common with ticagrelor, mainly due to dyspnea (a known adverse effect of ticagrelor [17, 88]) [87].”
BackgroundAtherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly
Violi, F., Loffredo, L., Carnevale, R., Pignatelli, P., & Pastori, D. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6963 · Cited by 125
Management of Left Main Coronary Artery Disease
Ramadan, R., Boden, W. E., & Kinlay, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008151 · Cited by 123
Turgeon, R. D., Koshman, S. L., Youngson, E. R. E., Har, B., Wilton, S. B., James, M. T., & Graham, M. M. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.6447 · Cited by 117
2024 Clinical practice guidelines for Stable coronary artery disease
Барбараш, О. Л., Karpov, Y. A., Panov, A. V., Akchurin, R. S., Alekyan, B. G., Alekhin, M. N., Aronov, D. M., HARUTYUNYAN, G., Belenkov, Y. N., Boytsov, S. A., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6110 · Cited by 153
Rapsomaniki, E., Thuresson, M., Yang, E., Blin, P., Hunt, P. R., Chung, S., Stogiannis, D., Pujades‐Rodríguez, M., Timmis, A., Denaxas, S., et al. (2016) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcw004 · Cited by 114
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
Kato, E. T., Morrow, D. A., Guo, J., Berg, D. D., Blazing, M. A., Bohula, E. A., Bonaca, M. P., Cannon, C. P., de Lemos, J. A., Giugliano, R. P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac577 · Cited by 122
“…Inhibition (PEACE), 15 Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)-TIMI 54, 16 and Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER)-TIMI 59.”
MethodSelf-citationAn Insight into Recent Advances on Platelet Function in Health and Disease
Chaudhary, P. K., Kim, S., & Kim, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116022 · Cited by 124
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Montalescot, G., Brieger, D. B., Dalby, A. J., Park, S., & Mehran, R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.053 · Cited by 112
Nylander, S., & Schulz, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13429 · Cited by 110
“Clopidogrel reduced endothelial injury (assessed as number of circulating EC) during PCI (Bonello et al., 2010) and improved vascular reactivity, either P2Y12 receptor-dependent (Hamilos et al., 2011; Siasos et al., 2015) or receptor-independent (Warnholtz et al., 2008; Willoughby et al., 2014).”
BackgroundEvaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Ferraro, R., Latina, J. M., Alfaddagh, A., Michos, E. D., Blaha, M. J., Jones, S. R., Sharma, G. V., Trost, J. C., Boden, W. E., Weintraub, W. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.078 · Cited by 114
Antithrombotic therapy for patients with STEMI undergoing primary PCI
Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.18 · Cited by 110
Vranckx, P., Valgimigli, M., Windecker, S., Steg, P. G., Hamm, C. W., Jüni, P., García‐García, H. M., van Es, G., & Serruys, P. W. J. C. (2016) · EuroIntervention · doi:10.4244/eijy15m11_07 · Cited by 107
Self-citationGurbel, P. A., Fox, K. A. A., Tantry, U. S., Cate, H. T., & Weitz, J. I. (2019) · Circulation · doi:10.1161/circulationaha.118.033580 · Cited by 105
Mitsis, A., & Gragnano, F. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16999201210195702 · Cited by 124
Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
Gallone, G., Baldetti, L., Pagnesi, M., Latib, A., Colombo, A., Libby, P., & Giannini, F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.052 · Cited by 104
P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation
Mansour, A., Bachelot‐Loza, C., Nesseler, N., Gaussem, P., & Gouin‐Thibault, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041391 · Cited by 107
Stone, G. W., Hochman, J. S., Williams, D. O., Boden, W. E., Ferguson, T. B., Harrington, R. A., & Maron, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.056 · Cited by 99
Bonaca, M. P., Bhatt, D. L., Ophuis, T. O., Steg, P. G., Storey, R. F., Cohen, M. C., Kuder, J., Im, K., Magnani, G., Budaj, A., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1017 · Cited by 99
Self-citationCao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 101
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae324 · Cited by 110
Emerging roles of thioredoxin cycle enzymes in the central nervous system
Patenaude, A., Murthy, M. R. V., & Mirault, M.-É. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4541-5 · Cited by 101
Gorog, D. A., Ferreiro, J. L., Ahrens, I., Ako, J., Geisler, T., Halvorsen, S., Huber, K., Jeong, Y., Navarese, E. P., Rubboli, A., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00901-2 · Cited by 100
“In these patients, standard 12-month DAPT with prasugrel or ticagrelor, or even prolongation of antiplatelet therapy beyond 12 months, should be considered for those at low risk of bleeding, for whom low-dose ticagrelor would be the agent of choice 93 .”
BackgroundSelf-citationWilliams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97
Aungraheeta, R., Conibear, A. E., Butler, M., Kelly, E., Nylander, S., Mumford, A. D., & Mundell, S. J. (2016) · Blood · doi:10.1182/blood-2016-03-707844 · Cited by 96
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 107
“Although the standard dose of ticagrelor is 90 mg twice daily when given with aspirin as part of DAPT in the context of ACS, the lower dose of 60 mg twice daily has been investigated in the PEGASUS-TIMI 54 trial (Table 1), compared to the standard 90 mg twice daily dose or placebo, on a background of aspirin in patien…”
MethodStatistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 98
Piccolo, R., Oliva, A., Avvedimento, M., Franzone, A., Windecker, S., Valgimigli, M., Esposito, G., & Jüni, P. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01197 · Cited by 94
Babeş, E. E., Bustea, C., Behl, T., Abdel‐Daim, M. M., Nechifor, A. C., Stoicescu, M., Brisc, M. C., Moisi, M. I., Gîtea, D., Iovanovici, D. C., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112772 · Cited by 97
Abu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.06.016 · Cited by 92
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction
Kereiakes, D. J., Yeh, R. W., Massaro, J. M., Cutlip, D. E., Steg, P. G., Wiviott, S. D., & Mauri, L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.485 · Cited by 92
Self-citationFunctional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Conflitti, P., Lyman, E. R., Sansom, M. S. P., Hildebrand, P. W., Gutiérrez‐de‐Terán, H., Carloni, P., Ansell, T. B., Yuan, S., Barth, P., Robinson, A. S., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01083-3 · Cited by 100
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90
Self-citationGaudino, M. F. L., Angiolillo, D. J., Franco, A. D., Capodanno, D., Bakaeen, F. G., Farkouh, M. E., Fremes, S. E., Holmes, D. R., Girardi, L. N., Nakamura, S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013032 · Cited by 93
D’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 91
Self-citationA Critical Appraisal of Aspirin in Secondary Prevention
Gargiulo, G., Windecker, S., Vranckx, P., Gibson, C. M., Mehran, R., & Valgimigli, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023952 · Cited by 93
Inflammation and Cardiovascular Disease: The Future
Arnold, N., Lechner, K., Waldeyer, C., Shapiro, M. D., & Köenig, W. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.50 · Cited by 93
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 99
Self-citationFanaroff, A. C., Cyr, D. D., Neely, M. L., Bakal, J. A., White, H. D., Fox, K. A. A., Armstrong, P. W., Lópes, R. D., Ohman, E. M., & Roe, M. T. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004755 · Cited by 86
The coagulation system in atherothrombosis: Implications for new therapeutic strategies
Olie, R. H., van der Meijden, P. E. J., & Cate, H. T. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12080 · Cited by 88
A polygenic risk score predicts atrial fibrillation in cardiovascular disease
Marston, N., Garfinkel, A. C., Kamanu, F., Melloni, G. E. M., Roselli, C., Jarolím, P., Berg, D. D., Bhatt, D. L., Bonaca, M. P., Cannon, C. P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac460 · Cited by 87
Self-citationPlatelets Are at the Nexus of Vascular Diseases
Lebas, H., Yahiaoui, K., Martos, R., & Boulaftali, Y. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00132 · Cited by 88
Sex Disparities in Myocardial Infarction: Biology or Bias?
Stehli, J., Duffy, S. J., Burgess, S. N., Kühn, L., Gulati, M., Chow, C. K., & Zaman, S. J. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.06.025 · Cited by 88
Platelet receptors as therapeutic targets: Past, present and future
Jamasbi, J., Ayabe, K., Goto, S., Nieswandt, B., Peter, K., & Siess, W. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0911 · Cited by 84
Self-citationMagnani, G., Storey, R. F., Steg, P. G., Bhatt, D. L., Cohen, M. C., Kuder, J., Im, K., Aylward, P. E., Ardissino, D., Isaza, D., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv482 · Cited by 84
“001 for 60 mg), however fatal bleeding or intracranial hemorrhage did not differ significantly [35].”
BackgroundSelf-citationEfficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54
Bonaca, M. P., Storey, R. F., Théroux, P., Steg, P. G., Bhatt, D. L., Cohen, M. C., Im, K., Murphy, S. A., Magnani, G., Ophuis, T. O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.768 · Cited by 83
Self-citationAntiplatelet Use in Ischemic Stroke
Kamarova, M., Baig, S. S., Patel, H., Monks, K. R., Wasay, M., Ali, A., Redgrave, J. N. E., Majid, A., & Bell, S. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211073009 · Cited by 93
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery
Banerjee, S., Angiolillo, D. J., Boden, W. E., Murphy, J. G., Khalili, H., Hasan, A., Harrington, R. A., & Rao, S. V. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.012 · Cited by 82
Park, K. H., Jeong, M. H., Ahn, Y., Ahn, T. H., Seung, K. B., Oh, D. J., Choi, D., Kim, H.-S., Gwon, H., Seong, I. W., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.044 · Cited by 79
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy
Moon, J. Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.004 · Cited by 81
Management of myocardial revascularisation failure: an expert consensus document of the EAPCI
Stefanini, G. G., Alfonso, F., Barbato, E., Byrne, R. A., Capodanno, D., Colleran, R., Escaned, J., Giacoppo, D., Kunadian, V., Lansky, A. J., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-20-00487 · Cited by 80
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Costa, F., & Valgimigli, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508692 · Cited by 80
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lópes, R. D., Al‐Khalidi, H. R., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 81
Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD
Müller, K., Chatterjee, M., Rath, D., & Geisler, T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0947 · Cited by 82
Abola, M. T. B., Golledge, J., Miyata, T., Rha, S., Yan, B. P., Dy, T. C., Ganzon, M. S. V., Handa, P. K., Harris, S., Jiang, Z., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.53660 · Cited by 81
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 89
Gurbel, P. A., Jeong, Y., Navarese, E. P., & Tantry, U. S. (2016) · Circulation Research · doi:10.1161/circresaha.115.307016 · Cited by 77
Radiomics applications in cardiac imaging: a comprehensive review
Polidori, T., Santis, D. D., Rucci, C., Tremamunno, G., Piccinni, G., Pugliese, L., Zerunian, M., Guido, G., Pucciarelli, F., Bracci, B., et al. (2023) · La radiologia medica · doi:10.1007/s11547-023-01658-x · Cited by 85
Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction
Schäfer, A., König, T., Bauersachs, J. K., & Akin, M. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101398 · Cited by 80
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Majithia, A., & Bhatt, D. L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310955 · Cited by 81
Self-citationBansilal, S., Bonaca, M. P., Cornel, J. H., Storey, R. F., Bhatt, D. L., Steg, P. G., Im, K., Murphy, S. A., Angiolillo, D. J., Kiss, R. G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.050 · Cited by 74
“Ticagrelor reduced the risk of major adverse cardiovascular (CV) events (MACE) (CV death, MI, or stroke), with an increase in nonfatal major bleeding (1).”
BackgroundSelf-citationDual antiplatelet therapy for secondary prevention of coronary artery disease
Degrauwe, S., Pilgrim, T., Aminian, A., Noble, S., Meier, P., & Iglesias, J. F. (2017) · Open Heart · doi:10.1136/openhrt-2017-000651 · Cited by 75
“PEGASUS-TIMI 54 randomised 21 162 patients with stable CAD, prior MI 1–3 years before inclusion and at high CV risk (≥1 high risk criteria: age ≥65 years, diabetes, second MI, multivessel CAD or chronic kidney disease) to aspirin monotherapy (75–150 mg daily) versus DAPT combining aspirin and ticagrelor (60 or 90 mg t…”
BackgroundMethodInfluentialNon–ST-Segment Acute Coronary Syndromes
Hedayati, T., Yadav, N., & Khanagavi, J. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2017.08.003 · Cited by 79
External Validation of the DAPT Score in a Nationwide Population
Ueda, P., Jernberg, T., James, S. K., Alfredsson, J., Erlinge, D., Ömerovic, E., Persson, J., Ravn‐Fischer, A., Tornvall, P., Svennblad, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.023 · Cited by 74
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
Capodanno, D., Baber, U., Bhatt, D. L., Collet, J., Dangas, G., Franchi, F., Gibson, C. M., Gwon, H., Kastrati, A., Kimura, T., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00725-6 · Cited by 72
Self-citationВалерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 86
Potent P2Y 12 Inhibitors in Men Versus Women
Lau, E. S., D, E. B. M., Murphy, S. A., Wiviott, S. D., Bonaca, M. P., Husted, S., James, S. K., Wallentin, L. C., Clemmensen, P. M., Roe, M. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.028 · Cited by 72
Self-citationAntithrombotic Therapy for Peripheral Artery Disease
Hussain, M. A., Al-Omran, M., Creager, M. A., Anand, S. S., Verma, S., & Bhatt, D. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.483 · Cited by 69
Self-citationCapodanno, D., & Angiolillo, D. J. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.10.023 · Cited by 70
Abu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.06.015 · Cited by 69
Metadata
- Authors
- Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., Bengtsson, O., Ophuis, T. O., Budaj, A., Theroux, P., Ruda, M., Hamm, C., Goto, S., Spinar, J., Nicolau, J. C., Kiss, R. G., Murphy, S. A., Wiviott, S. D., Held, P., Braunwald, E., & Sabatine, M. S.
- Affiliations
- Newark Beth Israel Medical Center (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- AstraZeneca (Sweden) (SE)
- Icahn School of Medicine at Mount Sinai (US)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Grochowski Hospital (PL)
- National Medical Research Center of Cardiology (RU)
- Justus-Liebig-Universität Gießen (DE)
- Tokai University (JP)
- Universidade de São Paulo (BR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-07
- Volume
- 372
- Issue
- 19
- Pages
- 1791-1800
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141358924
- Cited by
- 1,999
- References
- 32
- Citations by year
- 2026: 86 · 2025: 99 · 2024: 102 · 2023: 130 · 2022: 163 · 2021: 189 · 2020: 232 · 2019: 205 · 2018: 220 · 2017: 222 · 2016: 236 · 2015: 108
- FWCI
- 188.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- HAL (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (24390202)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, P2Y12 inhibitors, old myocardial infarction, dual antiplatelet therapy, long-term antiplatelet therapy, cardiovascular mortality, myocardial infarction, stroke, intracranial hemorrhage, aspirin, dose comparison, secondary prevention, bleeding risk, cardiovascular risk reduction
- MeSH terms
- Ticagrelor, Adenosine, Aged, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk, Intracranial Hemorrhages, Kaplan-Meier Estimate, Secondary Prevention, Purinergic P2Y Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
